Lupin Limited today announced the launch of a novel fixed-dose triple drug combination of Indacaterol, Glycopyrronium and Mometasone for managing inadequately controlled asthma amongst patients.
The company, however, expects a strong bounce back in the next quarter. “Our numbers are muted this quarter, but we expect a strong bounce back Q2 onwards," Lupin said.
Molnupiravir has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult COVID-19 patients who have a high risk of progression of the disease, including hospitalisation. 📰 Lupin Launches Antiviral Medication Molnupiravir Under Brand Molnulup for COVID-19 Treatment in Adults.
The drug has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult patients with COVID-19 and the ones who have a high risk of progression of the disease including hospitalisation.